Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection
Open Access
- 7 July 2005
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 56 (2), 388-395
- https://doi.org/10.1093/jac/dki243
Abstract
Objectives: We investigated the population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam in hospitalized patients. Patients and methods: A multicentre, randomized clinical trial was conducted in hospitalized patients with complicated intra-abdominal infection. Patients received piperacillin/tazobactam administered by either continuous infusion (13.5 g over 24 h, n = 130) or intermittent infusion (3.375 g every 6 h, n = 132). NONMEM was used to perform population pharmacokinetic analysis in a subset of patients (n = 56) who had serum samples obtained at steady-state for drug concentration analyses. Classification and regression tree analysis was used to identify the breakpoints of piperacillin PK-PD indexes in 94 patients with causative pathogen's MIC. Results: A one-compartment model was applied to fit the data. Creatinine clearance and body weight were the most significant variables to explain patient variability in piperacillin and tazobactam clearance and volume of distribution. The infusion method had no influence on PK parameters. For patients (n = 30) receiving intermittent infusion in the pharmacokinetic study, mean Cmax and half-life were 122.22 mg/L and 1.17 h for piperacillin, and 15.74 mg/L and 1.81 h for tazobactam. For patients (n = 26) receiving continuous infusion in the pharmacokinetic study, mean steady-state concentration was 35.31 ± 12.15 mg/L for piperacillin and 7.29 ± 3.28 mg/L for tazobactam. As a result of a low rate of failures (Conclusions: Intermittent infusion and continuous infusion of piperacillin and tazobactam provided sufficient drug exposure to treat those pathogens commonly implicated in intra-abdominal infections.This publication has 24 references indexed in Scilit:
- Simultaneous analysis of piperacillin and tazobactam in rabbits: application to pharmacokinetic studyBiomedical Chromatography, 2005
- Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo SimulationAntimicrobial Agents and Chemotherapy, 2004
- Population Pharmacokinetic Analysis of Nonlinear Behavior of Piperacillin during Intermittent or Continuous Infusion in Patients with Cystic FibrosisAntimicrobial Agents and Chemotherapy, 2003
- Population Pharmacokinetics of Continuous Infusion Piperacillin-TazobactamJournal of Infectious Disease Pharmacotherapy, 2002
- Divergence in MIC Distributions of Pseudomonas aeruginosa for Piperacillin and Piperacillin/TazobactamJournal of Infectious Disease Pharmacotherapy, 2001
- Single-dose pharmacokinetics of piperacillin and tazobactam in infants and childrenAntimicrobial Agents and Chemotherapy, 1994
- Pharmacokinetic characteristics of piperacillin/tazobactamIntensive Care Medicine, 1994
- Dose Dependence of Piperacillin PharmacokineticsChemotherapy, 1982
- Piperacillin: Human Pharmacokinetics After Intravenous and Intramuscular AdministrationAntimicrobial Agents and Chemotherapy, 1978
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976